Fortis Healthcare’s Post

📢All 12 manuscripts in the #SpecialIssue “#Hematologic #Malignancies: Challenges from Diagnosis to Treatment”, led by Dr. Ioanna Sakellari and Dr. Eleni Gavriilaki, Hematology Department and Dr. Eleni Gavriilaki, have been published! 🎉🎉 📌You are welcome to read via the following link: https://lnkd.in/dyADYnGy

New publication 📝 Retrospective analysis published in Hematology provides new insights for #AcuteLymphoblasticLeukemia, see: https://loom.ly/vnLhcDM #ALLsm #leusm #MedEducation

NEW from #ASH2023 | CD33-TIM3 dual #CARTcells enhance specificity of #AML treatment 🎥 🩸 Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, discusses the three main approaches and concepts within CAR T-cell therapy, highlighting her work on #CD33 and #TIM3 dual-targeting #CARTcells These cells are engineered to target only those cells expressing both the #CD33 and TIM3 #antigens, leading to an increase in specificty when treating #acutemyeloidleukemia (#AML) and allowing for the treatment of patients without the need for #allogeneic #stemcell #transplantation 💡 Give it a watch to learn more 👉 https://lnkd.in/eBWDW_ep #HemOnc American Society of Hematology #Leusm

NEW #MPN Session from #ASH23🩸 💬 This EXCLUSIVE discussion features leading experts Ruben Mesa, MD, Claire Harrison & Jean-Jacques Kiladjian, who discuss key updates in the #treatment and #management of #myeloproliferativeneoplasms (#MPNs) following the 65th ASH Annual Meeting and Exposition The experts cover a variety of topics, including #novelagents being explored in essential #thrombocythemia (ET), updates in the treatment of #polycythemiavera (PV), and novel combinations being evaluated in #myelofibrosis (MF) 🔦 Take a look 👉 https://lnkd.in/eXeXjSFj #HemOnc #MPNsm American Society of Hematology

Discover the latest developments in myeloma research from the Annual American Society of Hematology meeting. Clinical trial investigators share their abstract presentations from ASH delving deep into the key research takeaways. Watch Now: https://lnkd.in/gaawhHcq #ASH23

Especially lessons about clinical suspicion and complete blood cell abnormalities should be taught #bloodcancerawereness

#Congress | 🔎 What subjects were amplified by #HCPs through social media during #EHA2024? In June, took place the European Hematology Association (EHA) 2024 Hybrid Congress. The following pages provide a brief overview of the volume of conversations, the share of voice of clinical trials most discussed, or top hashtags. Moreover, discover a focus on #multiplemyeloma with the topics of discussions. Access the SML EHA2024 full report by clicking this link 👉 https://lnkd.in/e6-MYzHj

NEW #Thalassemia Sessions from #ASH23🩸 💬 In this session, leading experts Maria Domenica Cappellini & Kevin Kuo discuss exciting updates in #thalassemia presented at the 2023 ASH Annual Meeting and Exposition The experts cover several topics, including the promise of novel #genetherapies, ongoing #clinicaltrials in the field, and the value of #precisionmedicine 🔬 Take a look 👉 https://lnkd.in/e2-JsM7Y #HemOnc #MPNsm American Society of Hematology

How can your laboratory help reduce unnecessary complications for newly diagnosed Multiple Myeloma patients? Find out how from Prof. Guy Pratt who discusses how your laboratory can help guide blood test requesting and appropriate hematology referral. Download our case studies from hospitals in the United Kingdom, United States and Spain by here: https://hubs.li/Q02phTNn0

In this article featured in AJMC - The American Journal of Managed Care, presenters from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition discuss outcome disparities and the burden of multiple myeloma, which remains substantially higher among Black patients than White patients. Learn more!